FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940306721> ?p ?o ?g. }

• W2940306721 endingPage "776" @default.
• W2940306721 startingPage "766" @default.
• W2940306721 abstract "Aim: The approved indication for denosumab (120 mg) was expanded in 2018 to include skeletal-related event (SRE) prevention in patients with multiple myeloma (MM). Therefore, a cost-effectiveness analysis was conducted comparing denosumab with zoledronic acid (ZA) for SRE prevention in patients with MM from the national healthcare system perspective in a representative sample of European countries: Austria, Belgium, Greece, and Italy. Methods: The XGEVA global economic model for patients with MM was used to calculate incremental cost-effectiveness ratios (ICERs) for denosumab vs ZA over a lifetime horizon. Clinical inputs were derived from the denosumab vs ZA randomized, phase 3 study (20090482) in patients newly-diagnosed with MM, and comprised real-world adjusted SRE rates, serious adverse event (SAE) rates, treatment duration, dose intensity, progression-free survival (PFS), and overall survival (OS). Economic inputs comprised country-specific denosumab and ZA acquisition and administration costs, SRE and SAE management costs, and discount rates. Health utility decrements associated with MM disease progression, SRE and SAE occurrence, and route of administration were included. Results: Estimated ICERs (cost per quality-adjusted life-year [QALY] gained) for denosumab vs ZA in Austria, Belgium, Greece, and Italy were €26,294, €17,737, €6,982, and €27,228, respectively. Using 1-3 times gross domestic product (GDP) per capita per QALY as willingness to pay thresholds, denosumab was 69-94%, 84-96%, 79-96%, and 50-92% likely to be cost-effective vs ZA, respectively. Limitations: Economic inputs were derived from various sources, and time to event inputs were extrapolated from 20090482 study data. Conclusions: Denosumab is cost-effective vs ZA for SRE prevention in patients with MM in Austria, Belgium, Greece, and Italy, based on often-adopted World Health Organization thresholds. This conclusion is robust to changes in model parameters and assumptions. Cost-effectiveness estimates varied across the four countries, reflecting differences in healthcare costs and national economic evaluation guidelines." @default.
• W2940306721 created "2019-04-25" @default.
• W2940306721 creator A5011101421 @default.
• W2940306721 creator A5024041720 @default.
• W2940306721 creator A5036413377 @default.
• W2940306721 creator A5041407463 @default.
• W2940306721 creator A5050178081 @default.
• W2940306721 creator A5061825129 @default.
• W2940306721 creator A5071272497 @default.
• W2940306721 date "2019-04-29" @default.
• W2940306721 modified "2023-09-25" @default.
• W2940306721 title "A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy" @default.
• W2940306721 cites W1964947424 @default.
• W2940306721 cites W1967462478 @default.
• W2940306721 cites W1972714302 @default.
• W2940306721 cites W1978393082 @default.
• W2940306721 cites W1982055936 @default.
• W2940306721 cites W1997823019 @default.
• W2940306721 cites W1998628488 @default.
• W2940306721 cites W2016541062 @default.
• W2940306721 cites W2017845136 @default.
• W2940306721 cites W2024679877 @default.
• W2940306721 cites W2029303085 @default.
• W2940306721 cites W2036792267 @default.
• W2940306721 cites W2037064486 @default.
• W2940306721 cites W2048923316 @default.
• W2940306721 cites W2072518464 @default.
• W2940306721 cites W2086684921 @default.
• W2940306721 cites W2088116559 @default.
• W2940306721 cites W2100738529 @default.
• W2940306721 cites W2103327420 @default.
• W2940306721 cites W2103638671 @default.
• W2940306721 cites W2110958994 @default.
• W2940306721 cites W2130654618 @default.
• W2940306721 cites W2133104890 @default.
• W2940306721 cites W2137458001 @default.
• W2940306721 cites W2139814250 @default.
• W2940306721 cites W2146155626 @default.
• W2940306721 cites W2146461887 @default.
• W2940306721 cites W2153087381 @default.
• W2940306721 cites W2153630811 @default.
• W2940306721 cites W2162771614 @default.
• W2940306721 cites W2172421250 @default.
• W2940306721 cites W2175834422 @default.
• W2940306721 cites W2221425400 @default.
• W2940306721 cites W2273347348 @default.
• W2940306721 cites W2299833483 @default.
• W2940306721 cites W2339758831 @default.
• W2940306721 cites W2443618845 @default.
• W2940306721 cites W2493617532 @default.
• W2940306721 cites W2567289819 @default.
• W2940306721 cites W2590740624 @default.
• W2940306721 cites W2599639624 @default.
• W2940306721 cites W2603566358 @default.
• W2940306721 cites W2613642134 @default.
• W2940306721 cites W2625179498 @default.
• W2940306721 cites W2724826657 @default.
• W2940306721 cites W2760343979 @default.
• W2940306721 cites W2763711876 @default.
• W2940306721 cites W2782600446 @default.
• W2940306721 cites W2785739259 @default.
• W2940306721 cites W2789771233 @default.
• W2940306721 cites W2789852769 @default.
• W2940306721 cites W2790586235 @default.
• W2940306721 cites W2790648072 @default.
• W2940306721 cites W2791002232 @default.
• W2940306721 cites W2792953871 @default.
• W2940306721 cites W2794829127 @default.
• W2940306721 cites W2885117827 @default.
• W2940306721 cites W2894550010 @default.
• W2940306721 doi "https://doi.org/10.1080/13696998.2019.1606002" @default.
• W2940306721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30969797" @default.
• W2940306721 hasPublicationYear "2019" @default.
• W2940306721 type Work @default.
• W2940306721 sameAs 2940306721 @default.
• W2940306721 citedByCount "5" @default.
• W2940306721 countsByYear W29403067212019 @default.
• W2940306721 countsByYear W29403067212020 @default.
• W2940306721 countsByYear W29403067212021 @default.
• W2940306721 countsByYear W29403067212023 @default.
• W2940306721 crossrefType "journal-article" @default.
• W2940306721 hasAuthorship W2940306721A5011101421 @default.
• W2940306721 hasAuthorship W2940306721A5024041720 @default.
• W2940306721 hasAuthorship W2940306721A5036413377 @default.
• W2940306721 hasAuthorship W2940306721A5041407463 @default.
• W2940306721 hasAuthorship W2940306721A5050178081 @default.
• W2940306721 hasAuthorship W2940306721A5061825129 @default.
• W2940306721 hasAuthorship W2940306721A5071272497 @default.
• W2940306721 hasBestOaLocation W29403067211 @default.
• W2940306721 hasConcept C112930515 @default.
• W2940306721 hasConcept C114350782 @default.
• W2940306721 hasConcept C126322002 @default.
• W2940306721 hasConcept C162324750 @default.
• W2940306721 hasConcept C197934379 @default.
• W2940306721 hasConcept C2776286101 @default.
• W2940306721 hasConcept C2776364478 @default.
• W2940306721 hasConcept C2776541429 @default.
• W2940306721 hasConcept C3019080777 @default.

• next